I-131-Metaiodobenzylguanidine therapy with allogeneic cord blood stem cell transplantation for recurrent neuroblastoma.
Iodine-131-metaiodiobenzylguanidine (131I-MIBG) therapy combined with allogeneic cord blood stem cell transplantation (SCT) was used to treat a 4-year-old girl with recurrent neuroblastoma. The patient experienced relapse 2 years after receiving first-line therapies, which included chemotherapy, surgical resection, irradiation, and autologous peripheral SCT. Although 131I-MIBG treatment did not achieve complete remission, the size of the tumor was reduced after treatment. Based on our findings, we suggest that 131I-MIBG treatment with myeloablative allogeneic SCT should be considered as first-line therapy for high-risk neuroblastoma patients when possible.
Department of Pediatrics, Dokkyo Medical University School of Medicine, Mibu, Tochigi, Japan. syuya@dokkyomed.ac.jp
Yuya
Y
Sato
Hidemitsu
H
Kurosawa
Keitaro
K
Fukushima
Mayuko
M
Okuya
Susumu
S
Hagisawa
Kenichi
K
Sugita
Osamu
O
Arisaka
Anri
A
Inaki
Hiroshi
H
Wakabayashi
Ayane
A
Nakamura
Makoto
M
Fukuoka
Daiki
D
Kayano
Seigo
S
Kinuya
D019797:3-Iodobenzylguanidine / Q000627:therapeutic use*; D000310:Adrenal Gland Neoplasms / Q000628:therapy*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D036101:Cord Blood Stem Cell Transplantation; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007223:Infant; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D009364:Neoplasm Recurrence, Local; D009447:Neuroblastoma / Q000628:therapy*; D019275:Radiopharmaceuticals / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals; D019797:3-Iodobenzylguanidine